Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dexiang Gao

Showing results (141-150 of 166) with videos related to

Pageof 17
Sort By:
Oncotarget|April 13, 2016
The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistanceKevin S Quackenbush, Stacey Bagby, Wai Meng Tai, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 30, 2026
CLO26-116: Epigenetic Modulation Using Combined oral Decitabine/Cedazuridine (DEC-C) and Nivolumab in Unresectable or Metastatic Mucosal Melanoma: A Phase Ib/II TrialJessica S W Borgers, Cheng-Chang Wu, Theresa M Medina, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 29, 2026
CLO26-116: Epigenetic Modulation Using Combined oral Decitabine/Cedazuridine (DEC-C) and Nivolumab in Unresectable or Metastatic Mucosal Melanoma: A Phase Ib/II TrialJessica S W Borgers, Cheng-Chang Wu, Theresa M Medina, et al.
International Journal of Radiation Oncology, Biology, Physics|November 12, 2021
Results of a Multi-Institutional Phase 2 Clinical Trial for 4DCT-Ventilation Functional Avoidance Thoracic Radiation TherapyYevgeniy Vinogradskiy, Richard Castillo, Edward Castillo, et al.
Lung Cancer (Amsterdam, Netherlands)|November 30, 2024
The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutationsTejas Patil, Dexiang Gao, Alexander Watson, et al.
Journal of the National Cancer Institute|June 30, 2023
The programmed death ligand 1 interactome demonstrates bidirectional signaling coordinating immune suppression and cancer progression in head and neck squamous cell carcinomaCera Nieto, Bettina Miller, Nathaniel Alzofon, et al.
Frontiers in Oncology|November 30, 2019
IL-6 and IL-8 Are Linked With Myeloid-Derived Suppressor Cell Accumulation and Correlate With Poor Clinical Outcomes in Melanoma PatientsRichard P Tobin, Kimberly R Jordan, Puja Kapoor, et al.
Angewandte Chemie (International Ed. in English)|September 13, 2025
Bandgap Engineering of Graphene Nanoribbon via High-Pressure Topochemical SynthesisPeijie Zhang, Yunfan Fei, Qingchao Zeng, et al.
Journal of the American Chemical Society|September 9, 2020
Distance-Selected Topochemical Dehydro-Diels-Alder Reaction of 1,4-Diphenylbutadiyne toward Crystalline Graphitic NanoribbonsPeijie Zhang, Xingyu Tang, Yida Wang, et al.
Breast Cancer Research : BCR|August 4, 2018
A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancerJennifer R Diamond, S G Eckhardt, Todd M Pitts, et al.
Pageof 17

Showing results (141-150 of 166) with videos related to

Sort By:
Pageof 17
Oncotarget|April 13, 2016
The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistanceKevin S Quackenbush, Stacey Bagby, Wai Meng Tai, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 30, 2026
CLO26-116: Epigenetic Modulation Using Combined oral Decitabine/Cedazuridine (DEC-C) and Nivolumab in Unresectable or Metastatic Mucosal Melanoma: A Phase Ib/II TrialJessica S W Borgers, Cheng-Chang Wu, Theresa M Medina, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 29, 2026
CLO26-116: Epigenetic Modulation Using Combined oral Decitabine/Cedazuridine (DEC-C) and Nivolumab in Unresectable or Metastatic Mucosal Melanoma: A Phase Ib/II TrialJessica S W Borgers, Cheng-Chang Wu, Theresa M Medina, et al.
International Journal of Radiation Oncology, Biology, Physics|November 12, 2021
Results of a Multi-Institutional Phase 2 Clinical Trial for 4DCT-Ventilation Functional Avoidance Thoracic Radiation TherapyYevgeniy Vinogradskiy, Richard Castillo, Edward Castillo, et al.
Lung Cancer (Amsterdam, Netherlands)|November 30, 2024
The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutationsTejas Patil, Dexiang Gao, Alexander Watson, et al.
Journal of the National Cancer Institute|June 30, 2023
The programmed death ligand 1 interactome demonstrates bidirectional signaling coordinating immune suppression and cancer progression in head and neck squamous cell carcinomaCera Nieto, Bettina Miller, Nathaniel Alzofon, et al.
Frontiers in Oncology|November 30, 2019
IL-6 and IL-8 Are Linked With Myeloid-Derived Suppressor Cell Accumulation and Correlate With Poor Clinical Outcomes in Melanoma PatientsRichard P Tobin, Kimberly R Jordan, Puja Kapoor, et al.
Angewandte Chemie (International Ed. in English)|September 13, 2025
Bandgap Engineering of Graphene Nanoribbon via High-Pressure Topochemical SynthesisPeijie Zhang, Yunfan Fei, Qingchao Zeng, et al.
Journal of the American Chemical Society|September 9, 2020
Distance-Selected Topochemical Dehydro-Diels-Alder Reaction of 1,4-Diphenylbutadiyne toward Crystalline Graphitic NanoribbonsPeijie Zhang, Xingyu Tang, Yida Wang, et al.
Breast Cancer Research : BCR|August 4, 2018
A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancerJennifer R Diamond, S G Eckhardt, Todd M Pitts, et al.
Pageof 17